RACHEL AGUSTINES: Open Payments
NPI 1386617306 · LARGO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,252 in 207 payments from 20 companies in 2025. Trend: 2023 $3,596 · 2024 $3,139 · 2025 $4,252
Food & beverage: $4,252
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 33 | $610 |
| Axsome Therapeutics, Inc. | 19 | $570 |
| Neurocrine BioSciences, Inc. | 17 | $430 |
| Otsuka America Pharmaceutical, Inc. | 17 | $337 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $323 |
| E.R. Squibb & Sons, L.L.C. | 11 | $260 |
| Teva Pharmaceuticals USA, Inc. | 24 | $260 |
| Noven Therapeutics, LLC | 12 | $232 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $218 |
| ABBVIE INC. | 7 | $191 |
Products named: Qelbree, Auvelity, INGREZZA, REXULTI, CAPLYTA, COBENFY, Xelstrym, AUSTEDO XR.
Industry payments across FL — which companies pay providers there.
